Ontario expands use of biosimilar drug treatments

By Susan Yellin | Dec. 26, 2022, 9:53 a.m.

Flash | Regulation | Medication

Photo: Unsplash | Laurynas Mereckas

Ontario Drug Benefit recipients who are on an originator biologic will begin to transition to a Health Canada approved biosimilar version of the drug at the end of March.

This article is reserved to PRO Level subscribers

Discover the PRO Level

The most popular in Health

Canadians cutting back on care due to inflation

Federally funded not-for-profit studies acceptance of digital health services

TELUS Health appointed employee assistance program provider for Beneva

Headlines

Regulators publish eighth study of women on boards and in executive positions

Service at Ontario regulator exceeds standards

FP Canada calls for achievement award nominations

Related topics …

Flash

Service at Ontario regulator exceeds standards

Ontario regulator orders $90,000 in fines

More taxpayers affected by government debt recovery

General Insurance OmbudService deemed compliant with prescribed guidelines

Regulation

Regulators publish eighth study of women on boards and in executive positions

FP Canada to become single-source education and certification provider

Regulatory target timeframes published

Actuaries model new pension legislation impact

Medication

Canadians cutting back on care due to inflation

Mental health drugs and paramedical claims skyrocket

Cost of employer medical benefits forecast to rise 7.5 per cent in 2023

Ontario pharmacists can now prescribe for minor ailments

Ontario expands use of biosimilar drug treatments

Choose your payment method

Confirmation